Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

TIRZEPATIDE: 99,893 Adverse Event Reports & Safety Profile

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now
99,893
Total FAERS Reports
455 (0.5%)
Deaths Reported
5,527
Hospitalizations
99,893
As Primary/Secondary Suspect
718
Life-Threatening
629
Disabilities
Jan 20, 2026
FDA Approved
Eli Lilly and Company
Manufacturer
Prescription
Status

Drug Class: G-Protein-linked Receptor Interactions [MoA] · Manufacturer: Eli Lilly and Company · FDA Application: 215866 ·

Patent Expires: Jun 14, 2039 · First Report: 19620530 · Latest Report: 20250930

What Are the Most Common TIRZEPATIDE Side Effects?

#1 Most Reported
Incorrect dose administered
23,301 reports (23.3%)
#2 Most Reported
Injection site pain
10,989 reports (11.0%)
#3 Most Reported
Nausea
10,018 reports (10.0%)

All TIRZEPATIDE Side Effects by Frequency

Side Effect Reports % of Total Deaths Hosp.
Incorrect dose administered 23,301 23.3% 1 67
Injection site pain 10,989 11.0% 0 33
Nausea 10,018 10.0% 20 867
Off label use 7,007 7.0% 21 425
Extra dose administered 6,774 6.8% 1 32
Diarrhoea 5,463 5.5% 22 725
Vomiting 4,635 4.6% 27 1,004
Injection site haemorrhage 4,389 4.4% 0 12
Accidental underdose 3,897 3.9% 0 7
Injection site erythema 3,844 3.9% 0 14
Constipation 3,417 3.4% 6 341
Product dose omission issue 3,211 3.2% 0 47
Injection site bruising 2,665 2.7% 0 14
Drug ineffective 2,648 2.7% 0 44
Fatigue 2,301 2.3% 5 123
Blood glucose increased 2,240 2.2% 1 97
Abdominal pain upper 2,045 2.1% 6 229
Decreased appetite 2,041 2.0% 18 284
Injection site pruritus 1,947 2.0% 0 14
Headache 1,766 1.8% 2 96

Who Reports TIRZEPATIDE Side Effects? Age & Gender Data

Gender: 75.6% female, 24.4% male. Average age: 53.9 years. Most reports from: US. View detailed demographics →

Is TIRZEPATIDE Getting Safer? Reports by Year

YearReportsDeathsHosp.
2001 1 0 0
2002 4 0 0
2003 3 0 0
2005 1 0 0
2006 2 0 0
2010 1 0 0
2011 1 0 0
2012 2 0 0
2013 1 0 0
2014 1 0 0
2015 2 0 0
2016 3 0 2
2017 2 0 0
2018 13 0 3
2019 12 0 11
2020 25 0 10
2021 56 0 29
2022 3,538 4 215
2023 9,139 44 601
2024 14,149 75 1,004
2025 14,173 65 1,224

View full timeline →

What Is TIRZEPATIDE Used For?

IndicationReports
Product used for unknown indication 56,075
Weight control 17,354
Type 2 diabetes mellitus 14,571
Diabetes mellitus 5,209
Weight decreased 2,625
Glucose tolerance impaired 2,452
Obesity 700
Sleep apnoea syndrome 654
Insulin resistance 572
Glycosylated haemoglobin increased 564

TIRZEPATIDE vs Alternatives: Which Is Safer?

TIRZEPATIDE vs TISAGENLECLEUCEL TIRZEPATIDE vs TISLELIZUMAB TIRZEPATIDE vs TISOTUMAB VEDOTIN TIRZEPATIDE vs TISOTUMAB VEDOTIN-TFTV TIRZEPATIDE vs TITANIUM DIOXIDE\ZINC TIRZEPATIDE vs TIVICAY TIRZEPATIDE vs TIVOZANIB TIRZEPATIDE vs TIXOCORTOL PIVALATE TIRZEPATIDE vs TIZANIDINE TIRZEPATIDE vs TOBACCO LEAF

Official FDA Label for TIRZEPATIDE

Official prescribing information from the FDA-approved drug label.